Steroid Management in Inflammatory Bowel Disease

Introduction to Steroid Use

The European Crohn’s and Colitis Organisation recommends initiating prednisolone 40 mg daily as a single morning dose, tapering over 6-8 weeks, and never using steroids for maintenance therapy in patients with moderate to severe inflammatory bowel disease (IBD) flares 1, 2

For patients with moderate to severe ulcerative colitis, the American Gastroenterological Association suggests starting prednisolone 40 mg daily, which achieves 77% remission within 2 weeks 3, 4, 5
The American Gastroenterological Association recommends that doses of 60 mg/day increase adverse events without added benefit, making 40 mg optimal for patients with ulcerative colitis 6, 3
Combining oral and rectal steroids is superior to either alone for patients with ulcerative colitis, according to the European Crohn’s and Colitis Organisation 6, 3
Doses below 15 mg daily are ineffective for active ulcerative colitis, as stated by the American Gastroenterological Association 6, 3, 4
For patients with Crohn's disease, the Crohn’s and Colitis Foundation of America recommends using prednisone 0.5-0.75 mg/kg/day (higher dose for more severe disease) with tapering over 17 weeks, achieving 60% remission (NNT=3) 6, 3, 4
Alternatively, the Crohn’s and Colitis Foundation of America suggests that prednisone 1 mg/kg/day achieves 83% remission over 18 weeks (NNT=2) for patients with Crohn's disease 6, 3, 4
For ileocecal Crohn's disease specifically, the European Crohn’s and Colitis Organisation recommends budesonide 9 mg daily as an appropriate first-line alternative with reduced systemic toxicity 6, 3, 4

The American Gastroenterological Association recommends tapering prednisolone over 6-8 weeks once clinical response is achieved in patients with IBD 1, 2
Too rapid reduction associates with early relapse in patients with IBD, according to the European Crohn’s and Colitis Organisation 6, 3, 4
The American Gastroenterological Association suggests monitoring closely as dose decreases below 15 mg, as this is when disease relapse commonly occurs in patients with IBD 6, 3, 4

The European Crohn’s and Colitis Organisation recommends escalating to steroid-sparing therapy if patients require ≥2 corticosteroid courses within a calendar year, have disease relapse as steroid dose reduces below 15 mg, or relapse within 6 weeks of stopping steroids 6, 3, 4
When steroid dependency is identified, the American Gastroenterological Association suggests initiating thiopurines (azathioprine 2-2.5 mg/kg/day or 6-mercaptopurine 1-1.5 mg/kg/day), anti-TNF therapy, vedolizumab, or tofacitinib rather than repeating steroid courses 1, 2

The European Crohn’s and Colitis Organisation recommends budesonide MMX 9 mg daily for mild to moderate ulcerative colitis (especially left-sided disease) when patients wish to avoid systemic steroids 1, 2
The American Gastroenterological Association suggests beclomethasone dipropionate 5 mg daily for 4 weeks as an alternative for ulcerative colitis when 5-ASA fails 1, 2
The European Crohn’s and Colitis Organisation recommends budesonide (Entocort) 9 mg daily for ileocecal Crohn's disease—slightly less effective than prednisolone but with better safety profile 6, 3, 4

Approximately 50% of patients experience short-term adverse effects including acne, edema, sleep disturbance, mood changes, glucose intolerance, and dyspepsia, according to the American Gastroenterological Association 1, 2
Adverse events are significantly more frequent at 60 mg/day versus 40 mg/day without added benefit, as stated by the European Crohn’s and Colitis Organisation 6, 3
High-dose steroids (≥20 mg prednisolone daily) significantly increase risk of respiratory tract infection, opportunistic infection, and septicemia, according to the American Gastroenterological Association 7
The American Gastroenterological Association recommends adding PCP prophylaxis if >3 weeks of immunosuppression expected at doses >30 mg prednisone equivalent daily 7
The American Gastroenterological Association suggests starting proton pump inhibitor for GI prophylaxis during corticosteroid use 7

Corticosteroids have NO role in maintenance therapy for either ulcerative colitis or Crohn's disease, as stated by the European Crohn’s and Colitis Organisation 6, 3, 4, 5

The British Society of Gastroenterology strongly recommends systemic corticosteroids as the initial treatment for moderate‑to‑severe, uncomplicated luminal Crohn’s disease in hospitalized adults, citing high‑quality evidence. 8, 9

The European Crohn’s and Colitis Organisation advises that, at the time of initial presentation, clinicians should consider early introduction of biologic therapy for patients with extensive small‑bowel involvement or poor prognostic features, to avoid prolonged steroid exposure. 8, 9

Patients presenting with any of the following should receive biologic therapy rather than relying on steroids alone:

The British Society of Gastroenterology states unequivocally that systemic corticosteroids must never be used for maintenance therapy in Crohn’s disease because of toxicity and complete lack of efficacy; this recommendation has 100 % agreement and is supported by strong evidence. 8, 9